Posted by Michael Wonder on 22 May 2024
Protecting Australians from unsafe compounding of replica weight loss products
22 May 2024 - The Albanese Government is acting to protect Australians from the risks posed by injecting potentially unsafe and dangerous compounded replicas of weight loss products.
Compounded glucagon-like peptide-1 receptor agonists products are not identical to the TGA-approved products Ozempic (semaglutide) or Mounjaro (tirazapetide). Unlike TGA approved products, pharmacy compounded products are not clinically evaluated by the independent regulator for safety, quality or efficacy.
